* ProCyte Corp., of Kirkland, Wash., began Phase I/II studies ofIamin-1B solution for ulcerative colitis. Iamin-1B solution is apeptide-copper compound that is believed to attract cells involved intissue repair.

* SunPharm Corp., of Jacksonville, Fla., said the managingunderwriter of its initial public offering last month, RoyceInvestment Group Inc., exercised its option to purchase 165,000units to cover overallotments. SunPharm received $1.15 million fromthe sale, bringing the total raised from the IPO to $8.85 million. Theunits equal one share of common stock and one warrant redeemableat $7 per share.

* Quintiles Transnational Corp., of Research Park Triangle, N.C.,established a subsidiary in Singapore, Quintiles East Asia Pte. Ltd.,to expand its operations to China, Maylasia, Indonesia, Thailand,Indochina and the Philippines.

* International Murex Technologies Corp., of Atlanta, launched thesale of its Murex Hybrid Capture DNA test for cytomegalovirus inEurope. The DNA probe-based diagnostic is the first product basedon a collaboration between Murex and Digene Diagnostics Inc., ofSilver Spring, Md.

* Sherer Healthcare Inc., of New York, and Derma Sciences Inc., ofOld Forge, Pa., extended the deadline until Feb. 28 for theirinvitation to shareholders of ProCyte Corp., of Kirkland, Wash., tocall a special meeting to consider a takeover by Sherer and Derma.

(c) 1997 American Health Consultants. All rights reserved.